Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
Azitra reported ex vivo results showing ATR-COSF, a filaggrin-based cosmetic candidate, reduced the appearance of fine lines and wrinkles by roughly 15% at 3 hours and about 50% at 48 hours in human skin explants, while the vehicle control worsened. In a face-lift skin model, the 4% formulation outperformed both the 2% formulation and vehicle across elasticity measures at 6 hours. A first-in-human study of 4% ATR-COSF in approximately 30 subjects is planned, with initial data expected by year end; detailed results will be presented at BIO-Europe on November 10, 2026.
Key figures
- Drug Name
- ATR-COSF
- Phase Of Trial
- first-in-human
- First in human subjects
- 30
- Egfri rash us population
- ~150,000
- Ex vivo wrinkle reduction 3h
- ~15%
- Future financing instruments
- $5.25 million to $10.5 million
- Ex vivo wrinkle reduction 24h
- ~20%
- Ex vivo wrinkle reduction 48h
- ~50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.